Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y$_{12}$ receptor antagonist used to reduce the thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
## Primary Indications
* Acute Coronary Syndrome (ACS)
## Adult Dosing
* **ACS:**
* Loading Dose: 180 mg orally once.
* Maintenance Dose: 90 mg orally twice daily for at least 12 months.
* If treated with percutaneous coronary intervention (PCI): 90 mg orally twice daily can be continued beyond 12 months in select patients based on risk assessment.
* If a patient cannot tolerate ticagrelor or has a history of stroke/TIA, consider alternative antiplatelet therapy after the initial treatment period.
## Pediatric Dosing
Dosing in pediatric patients is not established.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Data are limited in severe hepatic impairment; use with caution.
* **Renal Impairment:** No dose adjustment is recommended for mild to moderate renal impairment. Data are limited in severe renal impairment (CrCl < 30 mL/min); use with caution.
## Contraindications
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
## Adverse Effects
* **Most Common:** Bleeding (including fatal and life-threatening), dyspnea, bradyarrhythmia, ventricular pauses.
* **Serious:** Major bleeding, minor bleeding, thrombocytopenia, angioedema.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) as this may increase ticagrelor exposure. Caution with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) as this may decrease ticagrelor exposure.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and consider risks/benefits.
* **CYP2C19 Substrates:** Ticagrelor is a substrate of CYP2C19. Concomitant use with CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) may increase ticagrelor exposure. The clinical significance is unclear, but avoid high-dose proton pump inhibitors if possible.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Heart Rate:** Monitor for bradycardia, especially in patients with pre-existing bradycardia risk factors.
* **Renal and Hepatic Function:** Baseline and periodic monitoring may be considered.
## Clinical Pearls
* Ticagrelor is a reversible P2Y$_{12}$ inhibitor, which may allow for faster return of platelet function compared to clopidogrel if urgent surgery is needed.
* Dyspnea is a common side effect and is not necessarily indicative of a cardiac event. If severe, consider dose reduction or discontinuation.
* For patients switching from clopidogrel or prasugrel to ticagrelor, no loading dose is needed if the last dose of the previous agent was taken within 24 hours.
* For patients switching from ticagrelor to clopidogrel or prasugrel, a loading dose of the new agent should be administered.
* Ticagrelor should be taken for at least 12 months in ACS patients, even if aspirin is discontinued.
***
*Disclaimer: This information is intended for clinical professionals and should be used as a quick reference. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Local protocols may also dictate specific treatment decisions.*
